<DOC>
	<DOC>NCT01318733</DOC>
	<brief_summary>A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.</brief_summary>
	<brief_title>Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<criteria>Male or female who is at least 18 years of age or older. A clinical diagnosis of facial rosacea. A Clinician Erythema Assessment (CEA) score of ≥3 at Screening and at Baseline (prior to study drug application). A Patient Self Assessment (PSA) score of ≥3 at Screening and at Baseline (prior to study drug application). Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as perioral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression. Previous refractive eye surgery such as photorefractive keratectomy (PRK), laserassisted subepithelial keratectomy (LASEK), or laserassisted in situ keratomileusis (LASIK). Current treatment with monoamine oxidase (MAO) inhibitors. Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alphaagonists. Less than 3 months stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rosacea</keyword>
</DOC>